APP and Alzheimer disease: Employing the TASTPM mouse, a different APP/PS1 model of AD where plaque pathology, gliosis, and cognitive impairment are observed at around 6 months of age, Grillo and colleagues delivered a 1072 nm wavelength light (pulsed at 600 Hz with a duty cycle of 300 μs, 5 mW/cm2) in 6-minute sessions for two consecutive days, bi-weekly for 5 months [31].